Genetically Modified T Cells Against Ovarian Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: OC-IgT cells.
- Who it may be relevant to
- Registry conditions: Ovarian Cancer. Basic parameters: 18 years — 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)
Overview
The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
Detailed description
Ovarian cancer (OC) is a cancer that forms in or on an ovary. The majority of OC arises from the epithelium (outer lining) of the ovary. In 2015 OC was found in 1.2 million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most common cancer and the eighth-most common cause of death from cancer. Treatment for OC consists of surgery, chemotherapy, radiotherapy and sometimes, novel immunotherapies. The best treatment options depend on many factors, including the type of OC, its stage and grade, as well as the general health of the patient.
Adoptive immunotherapy with cytotoxic T lymphocytes reactive with specific antigens has proven to be effective. Novel chimeric antigen receptor gene modified T cell (CART) based immunotherapy has demonstrated great successes in B cell malignancies. Here, the study aim is to evaluate the safety and efficacy of genetically engineered OC-specific and immune modulatory T cells in patients. The primary study objectives are to evaluate the safety of the investigational product, autologous OC-IgT cells, to subjects by IV and intratumoral injection. The secondary study objectives are (1) to evaluate the success rate of generating autologous OC-IgT cells in vitro, and (2) to determine the anti-OC efficacy of the OC-IgT cells.
Interventions
- Biological OC-IgT cells
Autologous human OC-IgT cells.
Primary outcome measures
- percentage of adverse effects after OC-IgT cells injection [Time frame: up to one month]
Secondary outcome measures (3)
- Rate of successful OC-IgT generation [Time frame: up to one month]
- Ability of OC-IgT cells to induce anti-ovarian cancer reaction [Time frame: after 1 month from OC-IgT cells infusion until 12 months after infusion]
- Ability of OC-IgT cells for anti-ovarian cancer reaction [Time frame: after 1 month from OC-IgT cell infusion until 24 months after infusion]
Eligibility criteria
Inclusion criteria
- Written, informed consent obtained prior to any study-specific procedures.
- Female patients ≥ 20 years.
- Eastern Cooperative Oncology Group (ECOG) PS of 0, 1 or 2.
- Life expectancy ≥ 3 months.
- Able to comply with the protocol.
- Histologically confirmed and documented high risk International Federation of Gynecology and Obstetrics (FIGO): Stage III-IV.
- Complete remission after salvage treatment for first recurrence.
- Not pregnant, and on appropriate birth control if of childbearing potential.
- Adequate bone marrow reserve with ·absolute neutrophil count (ANC) ≥ 1000/mm3.
·Platelets ≥100,000/mm3.
- Adequate renal and hepatic function with ·Serum creatinine ≤ 2 x upper limit of normal (ULN). ·Serum bilirubin ≤ 2 x ULN.
- aspartate aminotransferase (AST)/ALT ≤ 2 x ULN.
- Alkaline phosphatase ≤ 5 x ULN.
- Serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.
Exclusion criteria
1.Patients with:
- Non-epithelial ovarian cancer.
- Ovarian tumors with low malignant potential (i.e. borderline tumors).
- Synchronous primary endometrial carcinoma and ovarian cancer. 2.Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure (prior, current or planned treatment).
Previous experience of gene-engineered T cell therapy 4.Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
5.Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
6.Pregnant or lactating females. 7.Inadequate bone marrow function:
·Absolute neutrophil count < 1.0 x 109/L.
- Platelet count < 100 x 109/L.
- Hb < 9 g/dL. 8. Inadequate liver and renal function:
- Serum (total) bilirubin > 1.5 x ULN.
- AST \& ALT > 2.5 x ULN (> 5 x ULN in patients with liver metastases).
- Alkaline phosphatase > 2.5 x ULN (or > 5 x ULN in case of liver metastases or > 10 x ULN in case of bone metastases).
- Serum creatinine >2.0 mg/dl (> 177 μmol/L).
- Urine dipstick for protein uria should be < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate < 1 g of protein/24 hr.
9\. Serious active infection requiring i.v. antibiotics at during screening. 10. Subject infected with HIV (HIV antibody positive), Treponema pallidum antibody positive or TB culture positive.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Shenzhen Geno-immune Medical Institute — Shenzhen
Identifiers
NCT: NCT03184753 · GIMI-IRB-17002